Lead Author, publication date | Name of study or source of participants | Study design | Patient population | Location | Baseline year of study | Age group | Males (%) | Allocation concealment | Blinding to subjects | Blinding to carers | Aspirin dose | Medication compliance (%) | Duration of therapy (years) | Completeness of follow-up | Trial participants with diabetes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peto, 1988 | BMD | Randomised, open label with no placebo | Healthy male doctors | UK | 1978–1979 | 19–90 | 100.0 | No | No | No | 500 mg daily | NR | 5.6 | Unclear | 101 |
PHS Steering Committee, 1989 | PHS | RCT, double blinded | Healthy male doctors | USA | 1982 | 40–84 | 100.0 | Unclear | Yes | Yes | 325 mg every other day | NR | 5.0 | 99.7 | 533 |
ETDRS Investigators, 1992 | ETDRS | RCT, double blinded | Participants with type 1 and 2 diabetes | USA | 1980–1985 | 18–70 | 56.5 | Unclear | Yes | Yes | 650 mg daily | 91.8 | 5.0 | 94.7 | 3711 |
MRC, 1998 | TPT | Randomized, placebo controlled. Factorial with initial parallel group phase | Patients at high risk for IHD | UK | 1989–1994 | 45–69 | 100.0 | Adequate | Yes | Yes | 75 mg daily | NR | 6.7 | 98.9 | 68 |
Hansson, 1998 | HOT | RCT, double blinded | Participants with hypertension | Multiple countries | 1992–1994 | 50–80 | NR | Adequate | Yes | Yes | 75 mg daily | NR | 3.8 | 97.4 | 1501 |
Sacco, 2003 | PPP | Randomised open trial with 2 × 2 factorial design | Participants > 50 years with one or more CV risk factors | Italy | NR | 64.3* | 48.2 | Adequate | No | No | 100 mg daily | 71.8 | 3.6 | 99.3 | 1031 |
Ridker, 2005 | WHS | RCT, double blinded, 2 x 2 factorial | Healthy female health professionals | USA | 1993 | ≥ 45 | 0.0 | Unclear | Yes | Yes | 100 mg on alternate days | NR | 10.1 | 99.4 | 1027 |
Belch, 2008 | POPADAD | RCT, double blinded, 2 x 2 factorial | Patients ≥ 40 years with type 1 and 2 diabetes, ABP <=0.99 | Scotland | NR | ≥ 40 | 44.1 | Adequate | Yes | Yes | 100 mg daily | 50.0 | 6.7 | 99.5 | 1276 |
Ogawa, 2008 | JPAD | Randomised open label with blinded end point assessment | Patients with type 2 diabetes | Japan | 2002 | 65.0* | 55.0 | Adequate | No | No | 81 or 100Â mg daily | 90.0 | 4.4 | 92.4 | 2539 |
Ikeda, 2014 | JPPP | Randomised open label, parallel group | Elderly with multiple atherosclerotic risk factors | Japan | 2005–2007 | 60–85 | NR | Adequate | No | No | 100 mg daily | 76.0 | 5.0 | ~ 98.7 | 4903 |
McNeil, 2018 | ASPREE | RCT, double blind | Community dwelling free of CVD, disability, dementia | USA, Australia | 2010–2014 | ≥ 65 | 74.0 | Adequate | Yes | Yes | 100 mg daily | 70.0 | 4.7 | 98.5 | 2057 |
ASCEND Study Group, 2018 | ASCEND | RCT, double blind | Patients identified from diabetes registers or general practices | UK | 2005–2017 | ≥ 40 | 63.0 | Adequate | Yes | Yes | 100 mg daily | 70.0 | 7.4 | 99.1 | 15,480 |